Yep, it's not like we're gambling on a reverse merger to go through. It already happened. What flippers could be missing on this play, unfortunately, is that TXTM is really now more like a worldwide pharmaceutical/biopharma play in its infancy; they're in a position to provide medical grade cannabis products worldwide, along with a cost structure that no one can compete with, IMO.
Market Data 
Markets 
AI
